Clinical Trials Logo

Neutropenia, Febrile clinical trials

View clinical trials related to Neutropenia, Febrile.

Filter by:

NCT ID: NCT03003273 Terminated - Pediatric Cancer Clinical Trials

Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study

DALFEN
Start date: January 2017
Phase: Phase 3
Study type: Interventional

Pediatric patients with febrile neutropenia coming to Department of Medical Oncology with low risk features (culture awaited), will be started on intravenous antibiotics (Inj Cefoperazone+ Sulbactam ± Amikacin) on outpatient basis. Those patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. Antibiotics will be stopped in Arm-A and oral antibiotics, in place of intravenous antibiotics, will be started in Arm-B. The patients will be followed-up till ANC≥ 500, or reappearance of fever within follow-up of ≤ 10 days.

NCT ID: NCT02474550 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma

Start date: April 2015
Phase: N/A
Study type: Observational [Patient Registry]

This study was designed to review clincal outcomes of Diffuse Large B Cell Lymphoma (DLBCL) treated with R-CHOP chemotherapy in the era of pegylated-filgrastim. The investigators will prospectively collect clinical data and treatment outcome of patients with DLBCL who use prophylactic pegylated-filgrastim.